Search Results - "B O Plasencia Garcia de Diego"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions and emergency room visits. 66 months of follow-up by Romero Guillena, S. L., Plasencia Garcia de Diego, B. O., Gomez Gonzalez, J., Gotor Sánchez-Luengo, F.

    Published in European psychiatry (01-03-2023)
    “…IntroductionPaliperidone Palmitate 3-month formulation (PP3M) has shown a significantly longer time to relapse compared to placebo, with similar efficacy and…”
    Get full text
    Journal Article
  2. 2

    Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen. A 24 months follow-up and mirror image study by Romero Guillena, S L, F Gotor Sanchez-Luengo, B O Plasencia Garcia de Diego

    Published in European psychiatry (01-08-2024)
    “…IntroductionRelapse prevention is crucial in patients with schizophrenia, as repeated episodes can worsen psychopathology and functionality. There is strong…”
    Get full text
    Journal Article
  3. 3

    Alternative initiation regimen of paliperidone palmitate long-acting injectable by Menendez Gil, I.E., Romero Guillena, S.L., Plasencia Garcia De Diego, B.O.

    Published in European psychiatry (01-06-2022)
    “…IntroductionLong-acting injectable antipsychotics (LAIs) hold an important place in the treatment of psychosis. Knowledge of the best way to administer LAIs is…”
    Get full text
    Journal Article
  4. 4

    Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions. 60 months of follow-up by Romero Guillena, S.L., Plasencia Garcia De Diego, B.O., Gotor Sanchez-Luengo, F.

    Published in European psychiatry (01-06-2022)
    “…IntroductionPaliperidone Palmitate 3-month formulation (PP3M) has shown a significantly longer time to relapse compared to placebo, with similar efficacy and…”
    Get full text
    Journal Article
  5. 5

    Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen by Romero Guillena, S.L., Plasencia Garcia De Diego, B.O., Gotor Sanchez-Luengo, F., Gómez González, J.

    Published in European psychiatry (01-06-2022)
    “…IntroductionAripiprazole once-monthly is a long-acting intramuscular injectable formulation of aripiprazole. The starting dose can be administered by following…”
    Get full text
    Journal Article